medRxiv
August 7, 2025
Ben Deverett, Duan Li, Theresa R. Lii et al.
preprint
Structured Abstract Importance Ketamine has well known dissociative, analgesic, and antidepressant properties, but it is unknown whether the neurophysiologic effects that are associated with these properties can be modulated separately from one another. Given prior studies that link specific cortical oscillations with specific therapeutic effects, it is likely that modulating selective aspects...
European Neuropsychopharmacology
August 6, 2025
Tingting Liu, Jheng-Yan Wu, Po-Yu Huang et al.
6 citations
OBJECTIVE To evaluate the safety of esketamine in bipolar depression, focusing on suicide-related outcomes and manic switch across timeframe and demographic subgroups. METHODS This retrospective cohort study was conducted in May 2025 using data from the TriNetX global collaborative network. Adults with bipolar depression treated with esketamine plus a mood stabilizer were propensity...
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
August 5, 2025
Noor Zuhair Alsari, Nawfal Ali Mubarak, A. Al-Sabbagh
Background: Major depressive disorder (MDD) is a severe condition marked by persistent sadness and functional impairment. While electrocompulsive therapy (ECT) is effective for treatment-resistant cases, the comparative effects of propofol and ketamine as anesthetic agents remain unclear. Objective: To compare the effects of propofol and ketamine anesthesia on depression severity in patients...
Frontiers in Psychiatry
August 4, 2025
Fernando Mora, J. Ramos-Quiroga, Enrique Baca-García et al.
5 citations
Introduction Depression is a highly prevalent disease that severely impacts the life of patients. Inadequate response to at least two antidepressants despite adequacy of treatment and adherence is known as treatment-resistant depression (TRD), which entails a higher social and economic burden than non-resistant major depression. The lack of consensus on the definition of TRD and other aspects...
International Journal of Neuropsychopharmacology
August 1, 2025
P.-C. Wu, W. Lin, T.-P. Su et al.
Abstract Background As accumulating evidence suggests ketamine's antisuicidal properties, there has been growing interest in elucidating its underlying mechanisms and predictive factors for treatment response. However, the predictive power of several demographic and clinical characteristics varied across previous studies. Additionally, some potential predictors, such as baseline depression...
L'Encephale
August 1, 2025
Yara Bachir, Raymond Kassab, C. Hallal et al.
OBJECTIVE This case report explores the efficacy of intravenous Ketamine in treating active suicidal ideation in a 24-year-old female with comorbid major depressive disorder (MDD), borderline personality disorder (BPD), posttraumatic stress disorder (PTSD), and functional neurological disorder (FND). CASE DESCRIPTION The patient, with a history of multiple suicide attempts and...
The American journal of geriatric psychiatry
August 1, 2025
Ronesh Sukhdeo, Jocelyn K. Tamura, Christine E. Dri et al.
Ketamine has emerged as a promising treatment for major depression, though its efficacy and safety remain incompletely characterized in older adults. This systematic review synthesizes current evidence for ketamine in geriatric depression. A search of PubMed, EMBASE, and PsycINFO was conducted. Prospective clinical trials were included, with age restriction to participants ≥60 years applied at...
Neuropsychiatric Disease and Treatment
August 1, 2025
Yue-Yue Zhang, Qianqian Cai, Lingshan Wang et al.
Background & Aims Esketamine, a promising treatment for treatment-resistant depression, has shown potential advantages over traditional antidepressants. However, its mechanisms remain unclear. This study explores how esketamine alleviates depressive behaviors through activation of the BDNF/TrkB/PI3K/AKT signaling pathway. Methods Using a Chronic Unpredictable Mild Stress (CUMS) rat model,...
International Journal of Molecular Sciences
August 1, 2025
Łukasz P. Szałach, Klaudia Ciesielska-Figlon, A. Daca et al.
7 citations
Treatment-resistant depression (TRD) is associated with immune dysregulation. Ketamine, a rapid-acting antidepressant, may exert effects via immunomodulation. The aim was to examine ketamine’s impact on immune markers in TRD, including T-cell subsets, cytokines, and in vitro T-cell responses. Eighteen TRD inpatients received 0.5 mg/kg iv ketamine. Blood was sampled at baseline, 4 h, and 24 h to...
Psychedelic medicine (New Rochelle, N.Y.)
August 1, 2025
Kush V. Bhatt, Jason Compton, Em Ellerman et al.
1 citation
Mystical experiences are powerful experiences that may have therapeutic value. Ketamine, a dissociative anesthetic, has shown potential to induce mystical experiences. However, little research has explored this phenomenon, particularly in treatment-resistant depression. We analyzed clinical data from 60 veterans with treatment-resistant depression receiving a total of 189 ketamine treatments....